← All trials
NCT05457530
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2025
- First posted
- Jul 14, 2022
- Last posted
- Jul 14, 2022
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Prism Health North TexasLead sponsor
- MerckCollaborator
- Prism Health North TexasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.